Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Supplement study for pancreatic cancer patients withdrawn before it began

NCT ID NCT05360745

Symptom relief Sponsor: Fundacion para la Excelencia y la Calidad de la Oncologia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to see if a food supplement called ARACOMPLEX® could help maintain quality of life in patients with advanced pancreatic cancer receiving chemotherapy. The supplement contains maca extract, vitamins, and minerals. However, the trial was withdrawn before enrolling any participants, so no data were collected.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ARACOMPLEX® (a food supplement with maca extract, vitamins, and minerals)
What this could lead to
If it worked, this could point toward a simple nutritional supplement to help maintain quality of life during chemotherapy for advanced pancreatic cancer.
What could go wrong
The trial was withdrawn before enrolling any participants, so no results are available. Even if conducted, food supplements rarely have strong effects on cancer outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Started

Jun 2022

Finished

Sep 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients diagnosed with locally advanced or metastatic pancreatic cancer without previous chemotherapy treatment. * Patients for whom chemotherapy treatment has been indicated. * Adequate bone marrow function (neutrophils ≥1500 mm3, platelets ≥100,000 mm3), adequate liver function (bilirubin ≤1.5 times the upper limit of the normal range) * Adequate renal function (glomerular filtration rate greater than or equal to 90 ml/min/1.73). * ECOG functional stage 0-1 (Karnofsky ≥ 80). * Patients must agree to carry out study visits and procedures with precise instructions. Exclusion Criteria:. * Age ≥76 years. * Endocrine or acinar pancreatic cancer. * Serious systemic diseases such as: sepsis, heart failure, severe COPD, liver failure and chronic kidney disease. * Prior radiation to areas of measurable disease. * Chronic diarrhea. * Active infection. * Significant medical history of heart disease. * Pregnancy or lactation. * Impossibility of the patient, due to medical condition, to follow the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Locally advanced pancreatic carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Locally advanced pancreatic carcinoma Metastatic pancreatic cancer Quality of life

More trials for these conditions

Other studies related to the condition(s) this trial covers.